Treating Cannabis Dependence Improved Depression, Sleep, and Pain Even Without Full Abstinence | Research

The takeaway

Cannabis dependence treatment gradually reduced depression, anxiety, insomnia, and pain symptoms regardless of whether patients received nabiximols or placebo, and even when complete abstinence was not achieved.

People considering treatment for cannabis dependence, addiction medicine providers

Symptoms improved even without full abstinence

What the researchers found

Among participants with moderate-to-severe baseline scores, depression, anxiety, stress, and insomnia symptoms gradually decreased over 12 weeks of treatment. Pain decreased until week 12 but rebounded during the post-treatment period. Neither nabiximols vs placebo nor counseling sessions contributed significant explanatory power, suggesting treatment engagement itself drove improvement.

Why it matters

Many cannabis-dependent individuals also struggle with mood, sleep, and pain problems. This study shows that reducing cannabis use improves these comorbidities even without achieving full abstinence.

The numbers in context

128 participants; DASS-21, ISI, BPI at 5 timepoints; gradual symptom improvement over 12 weeks; pain rebounded post-treatment (weeks 12-24)

How the study worked

Secondary analysis of a 12-week double-blind placebo-controlled trial of nabiximols in 128 cannabis-dependent participants. DASS-21, Insomnia Severity Index, and Brief Pain Inventory measured at weeks 0, 4, 8, 12, and 24.

What this study cannot tell us

Secondary analysis. Cannot determine if symptom improvement caused reduced cannabis use or vice versa. Pain rebound post-treatment suggests ongoing pain management is needed.

How to read the evidence

Secondary analysis of a well-designed RCT, but the lack of medication effect limits causal conclusions about specific treatment mechanisms.

When this study was published

Published in 2022

The bigger picture

The finding that treatment engagement matters more than the specific medication challenges the all-or-nothing model of addiction treatment. Partial reduction in cannabis use still produced meaningful improvements.

Questions still open

Would longer treatment duration prevent the post-treatment pain rebound? Can partial cannabis reduction be formalized as a treatment goal rather than requiring full abstinence?

Common questions

Does quitting cannabis improve depression and sleep?

In this trial, reducing cannabis use (even without complete abstinence) was associated with gradual improvements in depression, anxiety, stress, and insomnia over 12 weeks of treatment.

Did nabiximols help with comorbid symptoms?

Neither nabiximols specifically nor the number of counseling sessions predicted symptom improvement. The key factor appeared to be treatment engagement and reduced cannabis use overall.

Read the original research

Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.

Drug and alcohol dependence, 234, 109388

View on PubMed ↗Publisher’s paper ↗

Citation

Montebello, Mark; Jefferies, Meryem; Mills, Llewellyn; Bruno, Raimondo; Copeland, Jan; McGregor, Iain; Rivas, Consuelo; Jackson, Melissa A; Silsbury, Catherine; Dunlop, Adrian; Lintzeris, Nicholas. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.. Drug and alcohol dependence, 234, 109388. https://doi.org/10.1016/j.drugalcdep.2022.109388